Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Article in Russian | MEDLINE | ID: mdl-8820676

ABSTRACT

High effectiveness of C.burnetii strain M-44 was confirmed in experimental studies on subcutaneously immunized guinea pigs ¿correction of pig] after their intratracheal infection with the virulent culture of the infective agent. The study revealed that the dose necessary for the enteral immunization of guinea pigs and monkeys was 10(4.8) -- 10(5.0) times less than that needed for the oral immunization of the animals. Live enteral vaccine obtained on the basis of this strain possessed sufficiently pronounced immunogenic and protective properties, protecting 75% of immunized monkeys from subcutaneous infection with C.burnetii virulent culture.


Subject(s)
Coxiella burnetii/immunology , Q Fever/prevention & control , Rickettsial Vaccines/immunology , Animals , Coxiella burnetii/pathogenicity , Dose-Response Relationship, Immunologic , Guinea Pigs , Immunization/methods , Macaca fascicularis , Papio , Q Fever/immunology , Rats , Vaccines, Attenuated/immunology , Virulence
2.
Vestn Ross Akad Med Nauk ; (2): 39-44, 1993.
Article in Russian | MEDLINE | ID: mdl-7688619

ABSTRACT

Oral and dermal administrations of vaccinia virus into rabbits, guinea pigs, and monkeys demonstrated a milder (without homeostasis disturbance) course of the vaccinal process with oral immunization, intensive immunity forming in minimal sensitization of the body was compared with dermal one. The results of revaccination in adults with oral smallpox vaccine and primary immunization in Ethiopia showed that oral immunization with vaccinia virus was safe, effective and lowly reactogenic. The comparative study of the preparation in remote revaccination (5 or more years later) proved its advantage over dermal vaccine. It consists in ecological safety (vaccinia virus excretion into the environment during 1 and 11 days, respectively, by 10-fold concentration reduction), reactogenicity (5 and 33% of common reactions, respectively) in the same immunogenicity.


Subject(s)
Immunization/methods , Smallpox Vaccine/administration & dosage , Vaccines, Synthetic/administration & dosage , Vaccinia virus/immunology , Viral Vaccines/administration & dosage , Administration, Cutaneous , Administration, Oral , Animals , Drug Evaluation , Drug Evaluation, Preclinical , Ethiopia , Haplorhini , Humans , Immunization, Secondary , Rabbits , Safety , Smallpox Vaccine/adverse effects , Smallpox Vaccine/immunology , Tablets , Vaccines, Synthetic/adverse effects , Vaccines, Synthetic/immunology , Viral Vaccines/adverse effects , Viral Vaccines/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...